Skip to content
Bored Studies
RecruitingPhase 2

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Pfizer · NCT06991257

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–79 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
620
US sites recruiting
28
Study start
June 19, 2025
Record last updated
October 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

Being studied: Placebo; Low Dose PF-07328948; Medium Dose PF-07328948; High Dose PF-07328948

Conditions: Heart Failure

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

This study is seeking participants who are:

Key Inclusion Criteria include

  • aged 18 years to \< 80 years
  • clinically confirmed to have a diagnosis of heart failure for at least 3 months
  • New York Heart Association Class II-IV symptoms
  • left ventricular ejection fraction greater than 40%
  • Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score \< 85
  • Six-minute walking distance greater than 75 meters

Key Exclusion Criteria include

  • Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body.
  • Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor.
  • History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes
  • Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor

Recruiting US locations

Study contacts (from the official record)

  • Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
All heart & blood pressure studies in California →